Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy

Devon Miller, John A. Livingston, Yeonhee Park, Kristi Posey, Sonia Godbole, Keith Skubitz, Steven I. Robinson, Mark Agulnik, Lara E Davis, Brian A. Van Tine, Angela C. Hirbe, Amanda Parkes

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Background: Sarcomas are rare diagnoses but are seen with relative frequency in adolescents and young adults and thus can present in pregnancy. We sought to study the administration of anthracyclines and/or ifosfamide in pregnancy-associated sarcomas. Patients and Methods: We conducted a multi-institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy. Chart review identified variables related to demographics, cancer diagnosis, therapies, and outcome of the patient and fetus. Wilcoxon rank-sum test compared two independent samples. Results: We identified 13 patients at seven institutions with sarcoma who received anthracyclines and/or ifosfamide during pregnancy, including four bone sarcomas and nine soft tissue sarcomas diagnosed at a mean gestational age of 16.7 ± 5.9 weeks. Only nine patients had live births (9/13, 69.2%), with mean gestational age of 30.8 ± 3.8 weeks at delivery. The four patients with pregnancy loss all received both doxorubicin and ifosfamide, with chemotherapy initiated at 15.5 weeks as compared with 21.3 weeks for those patients with live births (p = 0.016). Conclusion: In this multi-institutional study of sarcoma chemotherapy regimens administered during pregnancy, we found a high rate of fetal demise that was seen only in patients receiving both doxorubicin and ifosfamide and statistically more likely with chemotherapy initiation earlier in the second trimester. While limited by a small sample size, our study represents the largest study of sarcoma patients that received anthracyclines and/or ifosfamide in pregnancy thus far reported and supports development of an international registry to study concerns raised by our study.

Original languageEnglish (US)
Pages (from-to)3471-3478
Number of pages8
JournalCancer medicine
Issue number18
StatePublished - Sep 2022

Bibliographical note

Funding Information:
This work is supported financially by the National Natural Science Foundation of China under project No. 51272221

Publisher Copyright:
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.


Dive into the research topics of 'Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy'. Together they form a unique fingerprint.

Cite this